NCT07369895

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Chimeric Antigen Receptor T Cell (O&D-001) Injection Targeting BCMA and GPRC5D in the Treatment of Relapsed or Refractory Multiple Myeloma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: O&D BioTech Group CO., Limited · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D	Using the traditional 3+3 dose escalation method.

Timeline

• Start date: 2025-10-28
• Primary completion: 2028-03-28
• Completion: 2028-03-28
• First posted: 2026-01-27
• Last updated: 2026-01-27

Locations

1 site across 1 country: China